Comparative Pharmacology
Head-to-head clinical analysis: CEFAZOLIN IN DEXTROSE versus CEFOTAN IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFAZOLIN IN DEXTROSE versus CEFOTAN IN PLASTIC CONTAINER.
CEFAZOLIN IN DEXTROSE vs CEFOTAN IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking.
Cefotetan is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and cross-linking of peptidoglycan. It has broad-spectrum activity against gram-negative and gram-positive bacteria, including anaerobes, and is resistant to beta-lactamases.
1-2 g IV every 8 hours. For serious infections, up to 2 g IV every 6 hours.
1 to 2 g intravenously or intramuscularly every 12 hours for 5 to 10 days. Maximum dose 6 g daily.
None Documented
None Documented
1.8 hours in normal renal function. Prolonged to 12-24 hours in end-stage renal disease (CrCl <10 mL/min).
2.8-3.2 hours in normal renal function; prolonged to 12-30 hours in severe renal impairment (CrCl <10 mL/min).
Renal: 80-90% unchanged by glomerular filtration and tubular secretion. Biliary: minor (<1%). Fecal: negligible.
Primarily renal (76-85% unchanged in urine via glomerular filtration and tubular secretion); biliary excretion accounts for <10%, with small amounts in feces.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic